Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 20 от 100

Набира участници Фаза 2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Anal Carcinoma Cervical Carcinoma Malignant Female Reproductive System Neoplasm Rectal Carcinoma +2

This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.

Начало: 12.03.2026 Край: 31.12.2026 Възраст: от 50 г.

United States Ohio State University Comprehensive Cancer Center NCT07407647

Набира участници Фаза 3

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Начало: 12.03.2026 Край: 14.10.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +30 Bristol-Myers Squibb NCT07361510

Набира участници Фаза 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Начало: 11.03.2026 Край: 30.07.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +2 Hoffmann-La Roche NCT07287150

Набира участници

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Abnormal Uterine Bleeding (AUB) Endometrial Cancer Atypical Endometrial Hyperplasia Endometrial Hyperplasia With Atypia +1

This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.

Начало: 10.03.2026 Край: 24.04.2028 Възраст: от 18 г.

United States Exact Sciences Corporation NCT07544680

Набира участници

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

Gynecologycal Cancer

The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.

Начало: 10.03.2026 Край: 01.04.2027 Възраст: от 50 г.

United States Wake Forest University Health Sciences NCT07046936

Набира участници Фаза 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Adenocarcinoma Stage IVB Prostate Cancer AJCC v8

This phase I trial compares the effect of lutetium Lu 177 (177\^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177\^Lu-PSMA-617 alone in treating patients with prostate that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow and spread despite surgical or medical intervention to block androgen production (castration-resistant). 177\^Lu-PSMA-617, a type of radioconjugate, binds to a protein called PSMA, which is found on some prostate tumor cells. It gives off radiation that may kill the tumor cells. Sipuleucel-T, a type of vaccine and a type of cellular adoptive immunotherapy, is made from immune system cells. The cells are treated with a protein that is made by combining a protein found on prostate tumor cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate tumor cells. Giving 177\^Lu-PSMA-617 in combination with sipuleucel-T may be safe, tolerable, and/or effective compared to 177\^Lu-PSMA-617 alone in treating patients with metastatic castration-resistant prostate cancer.

Начало: 06.03.2026 Край: 26.07.2028 Възраст: от 18 г.

United States City of Hope Medical Center NCT07219147

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CRC (Colorectal Cancer)

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Начало: 05.03.2026 Край: 28.09.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 Incyte Corporation NCT07284849

Набира участници

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

NSCLC (Non-small Cell Lung Cancer)

This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.

Начало: 01.03.2026 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia Tau Medical Australia Pty Ltd NCT07122258

Набира участници Фаза 2

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Breast Cancer Residual Disease Triple Negative Breast Cancer (TNBC) Stage II/III

This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays. The primary objective of this study will be to evaluate ctDNA-based MRD status in high-risk, early-stage TNBC patients by defining the proportion of TNBC patients with MRD-only recurrence (ctDNA positive without radiographically measurable recurrence) during post-surgery surveillance. The secondary objectives will evaluate the safety, preliminary efficacy, and survival outcomes of using Dato-DXd in participants with MRD-only TNBC. Dato-DXd is an investigational antibody-drug conjugate (monoclonal antibody specific for TROP2 and a topoisomerase I (Topo-1) inhibitor) that has demonstrated promising efficacy in TNBC patients with a manageable safety profile.

Начало: 26.02.2026 Край: 01.11.2032 Възраст: от 18 г.

United States UNC Lineberger Comprehensive Cancer Center NCT07069595

Набира участници Фаза 1

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

Ovarian Cancer

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Начало: 13.02.2026 Край: 01.09.2027 Възраст: от 18 г.

United States Theolytics Limited NCT07211659

Набира участници Фаза 3

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Breast Cancer

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy

Начало: 10.02.2026 Край: 10.02.2031 Възраст: от 18 г.

China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NCT07400523

Набира участници Фаза 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IV EGFR Gene Mutation

Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

Начало: 01.02.2026 Край: 22.01.2028 Възраст: 18–75 г.

China Tianjin Medical University Cancer Institute and Hospita NCT07548060

Набира участници

A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI

Rectal Cancer

This project aims to use multi-temporal, multi-parameter MRI features, blood biomarkers, and clinical indicators to accurately assess pseudoprogression following immunotherapy in rectal cancer.

Начало: 01.02.2026 Край: 31.12.2029

China Peiyi Xie NCT07381322

Набира участници Фаза 2

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

IgA Monoclonal Gammopathy of Undetermined Significance

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.

Начало: 22.01.2026 Край: 01.05.2028 Възраст: от 18 г.

United States Fred Hutchinson Cancer Center NCT07209371

Набира участници

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Locally Advanced Breast Cancer Metastatic Breast Cancer

The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (LA/mBC), following on or after completing adjuvant endocrine therapy in routine clinical practice in China.

Начало: 21.01.2026 Край: 09.09.2029 Възраст: от 18 г.

China Hoffmann-La Roche NCT07347600

Набира участници Фаза 2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Advanced Breast Cancer

To evaluate the efficacy and safety of toripalimab in combination with investigator-selected chemotherapy in patients with recurrent or metastatic HER2-negative breast cancer who have failed prior systemic therapy.

Начало: 20.01.2026 Край: 01.08.2028 Възраст: от 18 г.

China Henan Cancer Hospital NCT07540533

Набира участници

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

Breast Cancer Her 2 Positive Breast Cancer

The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.

Начало: 15.01.2026 Край: 15.01.2027 Възраст: от 19 г.

Algeria Société Algérienne de Formation et Recherche en Oncolog NCT07542496

Набира участници Фаза 1/2

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Начало: 13.01.2026 Край: 02.08.2032 Възраст: от 18 г. Лечение

Australia, China, France +8 Novartis Pharmaceuticals NCT07190300

Набира участници Фаза 2/3

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Начало: 02.01.2026 Край: 12.08.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Bristol-Myers Squibb NCT07063745

Набира участници Фаза 2

Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer

Gastric Cancer Leucine-restricted Diet

Consistent with previous literature, the investigators postulate that a leucine-restricted diet is safe and well-tolerated in gastric cancer patients receiving neoadjuvant chemo-immunotherapy. Furthermore, the investigators propose that this dietary regimen promotes the activation of immune cells within the tumor microenvironment (TME). When combined with neoadjuvant chemo-immunotherapy, it demonstrates synergistic anti-tumor efficacy, thereby improving patient prognosis.

Начало: 01.01.2026 Край: 31.08.2027 Възраст: 18–70 г.

China Qilu Hospital of Shandong University NCT07537361

1 … 18 19 20 21 22 … 100